{"ticker": {"uuid": "63514fae-0e42-4c42-8279-b2f57416447a", "symbol": "IVA", "name": "Inventiva Sa", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Inventiva (ENXTPA:IVA) Refreshes Its Board, Is The 62% Discount Too Wide?", "summary": "Inventiva (ENXTPA:IVA) has recently revamped its board with three new independent members, drawing investor attention. The company's stock is currently trading at a 62% discount to analyst targets, with a narrative fair value of \u20ac10.09 compared to its current price of \u20ac3.82, fuel", "url": "https://simplywall.st/stocks/fr/pharmaceuticals-biotech/epa-iva/inventiva-shares/news/inventiva-enxtpaiva-refreshes-its-board-is-the-62-discount-t/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T15:40:49", "published_display": "15 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring", "summary": "Inventiva S.A. (NASDAQ: IVA) has completed the restructuring of its European Investment Bank (EIB) warrants, issuing approximately 15.7 million new warrants and canceling original EIB warrants from January 2024. This move, according to CEO Andrew Obenshain, strengthens the compan", "url": "https://finance.yahoo.com/markets/stocks/articles/inventiva-iva-announces-issuance-eib-085308516.html", "source_name": "Market source", "published_at": "2026-07-15T03:53:00", "published_display": "15 Jul 2026 03:53", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Inventiva (ENXTPA:IVA) Puts Its MASH Narrative To The Test After A Recent Rebound", "summary": "Inventiva (ENXTPA:IVA) stock has experienced mixed performance, with recent gains offset by longer-term declines, as investors focus on its clinical pipeline in MASH and rare diseases. The company's MASH drug, lanifibranor, is in a Phase III trial, with top-line results expected ", "url": "https://finance.yahoo.com/healthcare/articles/inventiva-enxtpa-iva-puts-mash-130821487.html", "source_name": "Market source", "published_at": "2026-07-12T12:40:27", "published_display": "12 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Issues 15.7 Million New Warrants to the EIB and Completes Its Refinancing", "summary": "Inventiva has completed the final step of its financial restructuring by issuing approximately 15.7 million new warrants to the European Investment Bank (EIB) and cancelling unredeemed old warrants. This action simplifies the capital structure by eliminating anti-dilutive mechani", "url": "https://www.ideal-investisseur.fr/en/stock-news/inventiva-issues-15-7-million-new-warrants-to-the-eib-and-completes-its-refinancing/22487.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-10T10:28:56", "published_display": "10 Jul 2026 10:28", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Inventiva S.A. Current Report (Foreign Issuer) | IVA SEC Filing - Form 6-K", "summary": "Inventiva S.A. has completed its warrant restructuring with the European Investment Bank (EIB), issuing 15,677,573 new EIB warrants and cancelling all remaining legacy Tranche B warrants. This move simplifies the company's capital structure by removing specific contractual anti-d", "url": "https://www.stocktitan.net/sec-filings/IVA/6-k-inventiva-s-a-current-report-foreign-issuer-57e82f83c317.html", "source_name": "Stock Titan", "published_at": "2026-07-10T04:41:07", "published_display": "10 Jul 2026 04:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants", "summary": "Inventiva has completed the final step of its EIB warrant restructuring, issuing approximately 15.7 million new warrants to the European Investment Bank and canceling remaining legacy warrants. This initiative, part of a broader refinancing effort, aims to strengthen Inventiva's ", "url": "https://www.globenewswire.com/news-release/2026/07/09/3325223/0/en/inventiva-announces-completion-of-the-eib-warrant-restructuring-with-the-issuance-of-new-eib-warrants.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T20:08:56", "published_display": "09 Jul 2026 20:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Appoints Three Independent Directors Ahead of Key Lanifibranor Phase", "summary": "Inventiva has appointed three independent directors, Dr. Barbara Krebs-Pohl, Dr. Anne Prener, and Camilla Soenderby, to its board, effective June 30, 2026. These appointments aim to strengthen expertise in clinical development, commercialization, and financial strategy as the bio", "url": "https://www.ideal-investisseur.fr/en/stock-news/inventiva-appoints-three-independent-directors-ahead-of-key-lanifibranor-phase/22421.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-09T10:15:00", "published_display": "09 Jul 2026 10:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva S.A. - American Depository Shares Stock 12\u2011Month Price Target Raised to $15.69, Implies 257% Upside", "summary": "Inventiva S.A. (IVA) has seen its average 12-month price target raised from $15.08 to $15.69 by a consensus of 7 analysts, with individual forecasts ranging from $10 to $26 per share. This new target implies a substantial 257% potential upside based on the July 8 closing price. T", "url": "https://www.tradingview.com/news/tradingview:31235dc3185b4:0-inventiva-s-a-american-depository-shares-stock-12-month-price-target-raised-to-15-69-implies-257-upside/", "source_name": "TradingView", "published_at": "2026-07-09T04:19:41", "published_display": "09 Jul 2026 04:19", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva (NASDAQ: IVA) shareholders approve most 2026 meeting resolutions", "summary": "Inventiva S.A. shareholders approved almost all resolutions at their Combined Shareholders\u2019 General Meeting on June 30, 2026, with a quorum of over 71%. The only resolution rejected was the 31st, which would have authorized share capital increases for a company savings plan, alig", "url": "https://www.stocktitan.net/sec-filings/IVA/6-k-inventiva-s-a-current-report-foreign-issuer-31be093c8415.html", "source_name": "Stock Titan", "published_at": "2026-07-06T10:11:48", "published_display": "06 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6IVA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Inventiva SA ADR (6IVA) for 2027 based on analyst ratings. It states that 10 analysts offer 1-year price forecasts, but the specific maximum and minimum estimates are not provided. The content also includes a disclaimer that it", "url": "https://www.tradingview.com/symbols/MUN-6IVA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-04T04:39:43", "published_display": "04 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVA News | INVENTIVA SA - ADR (NASDAQ:IVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE96OEFrRWxIU29XSlphbzI1SVl4U1dRNDdoeHpZSDk5anNOalZObkZnRmFHNWlteldxeXBTS1pGczYta1I2aU45bzJVWnVPMzVISjNWdXFzaUdYUQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:02+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVENTIVA", "summary": "Inventiva, a clinical-stage biopharmaceutical company, announced the results of its Combined Shareholders' General Meeting held on June 30, 2026. Shareholders adopted all resolutions except for the 31st, which was related to share capital increases for a company savings plan and ", "url": "https://via.ritzau.dk/pressemeddelelse/15030111/inventiva?publisherId=90446&lang=en", "source_name": "Via Ritzau", "published_at": "2026-07-02T19:39:38", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Maintains Inventiva(IVA.US) With Buy Rating", "summary": "Truist Financial has reiterated its Buy rating on Inventiva (IVA.US) stock. The firm's decision to maintain this rating suggests a positive outlook on Inventiva's future performance.", "url": "https://www.moomoo.com/news/post/72400019/truist-financial-maintains-inventiva-ivaus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-07-02T15:39:39", "published_display": "02 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Calls June 30, 2026 Shareholder Meeting to Approve 2025 Accounts and New Capital Authorities", "summary": "Inventiva has scheduled a shareholder meeting for June 30, 2026, to approve its 2025 accounts, decide on profit allocation, executive compensation, and undertake board renewals and new appointments, signifying a comprehensive governance update. Shareholders will also vote on exte", "url": "https://www.tipranks.com/news/company-announcements/inventiva-calls-june-30-2026-shareholder-meeting-to-approve-2025-accounts-and-new-capital-authorities", "source_name": "TipRanks", "published_at": "2026-07-01T03:10:41", "published_display": "01 Jul 2026 03:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva S.A. (IVA) is One of the Best Stocks Under $10 Offering More Than 50% Upside", "summary": "Inventiva S.A. (NASDAQ: IVA) has a strong bullish consensus from analysts, with all 9 providing Buy ratings and a median 1-year price target of $15.75, implying over 325% upside. The company recently announced financial updates, including repaying \u20ac62 million of EIB loans, buying", "url": "https://finance.yahoo.com/markets/stocks/articles/inventiva-iva-one-best-stocks-163452236.html", "source_name": "Market source", "published_at": "2026-07-01T01:40:11", "published_display": "01 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNZFN2bDBwellQZG9YQmNEUk1TU0RfN3VSTGZ4MEV1amRGZ09Oa1hrY2VVRnZqSzdRV0ZXeTI3SURoQ0xzaHZvTEhHYW1ISHZkTlh5dHNfci1UNTZNNUlGZ29qbmdraldINFN6N1JzMnNlX3VqdXVUU2ZlYXhYbjRSVlk1bmMxeUNpQWpNRThNdw?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Inventiva SA \u2013 AQUISEU:IVAP", "summary": "This article provides financial information for Inventiva SA (IVAP) listed on the Aquis Stock Exchange, specifically focusing on its forward price-to-earnings ratio. The page details that the market is currently closed and no trades have occurred for IVAP. It presents a structure", "url": "https://www.tradingview.com/symbols/AQUISEU-IVAP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T12:40:24", "published_display": "27 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Inventiva SA \u2013 EURONEXT:IVA", "summary": "This article provides the \"Price to earnings forward\" value for Inventiva SA (EURONEXT:IVA). It states that the period value and change are presented, with the data made by humans. The content is primarily a data point display within the TradingView platform.", "url": "https://www.tradingview.com/symbols/EURONEXT-IVA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:40:53", "published_display": "27 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA ADR Actuals & Estimates (LSX:A2P796)", "summary": "The article provides an overview of Inventiva SA ADR's financial actuals and estimates for its stock (LSX:A2P796) on the Lang & Schwarz Exchange. It highlights the availability of reported financial data and analyst estimates across various financial statements, allowing users to", "url": "https://www.tradingview.com/symbols/LSX-A2P796/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:40:53", "published_display": "27 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA ADR Actuals & Estimates (LS:A2P796)", "summary": "This page provides financial actuals and estimates for Inventiva SA ADR (LS:A2P796), allowing users to explore reported financial data and analyst estimates. It covers the income statement, balance sheet, and cash flow, enabling comparison of actual results with average, high, an", "url": "https://www.tradingview.com/symbols/LS-A2P796/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:53", "published_display": "26 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Inventiva SA (IVA) stock, based on analyst opinions. It details current stock performance, historical highs and lows, and financial metrics such as market capitalization, earnings, and revenue. The article also includes freque", "url": "https://www.tradingview.com/symbols/EURONEXT-IVA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T11:40:53", "published_display": "26 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA Actuals & Estimates (EURONEXT:IVA)", "summary": "This article provides an overview of Inventiva SA's (EURONEXT:IVA) financial actuals and estimates. It covers historical stock performance, analyst forecasts, market capitalization, earnings reports, and other key financial metrics. The article also addresses frequently asked que", "url": "https://www.tradingview.com/symbols/EURONEXT-IVA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:40:53", "published_display": "26 Jun 2026 11:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Inventiva SA \u2013 EURONEXT:IVA", "summary": "This article presents the enterprise value to EBITDA forward data for Inventiva SA (EURONEXT:IVA) as reported on TradingView. It details the financial metric value and its period, along with any changes, but without providing specific figures. The content appears to be a financia", "url": "https://www.tradingview.com/symbols/EURONEXT-IVA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T07:39:19", "published_display": "26 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA ADR Actuals & Estimates (NASDAQ:IVA)", "summary": "This article provides access to the financial actuals and estimates for Inventiva S.A. - American Depository Shares (NASDAQ:IVA). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics,", "url": "https://www.tradingview.com/symbols/NASDAQ-IVA/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T06:39:19", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Inventiva SA \u2013 EURONEXT:IVA", "summary": "The article provides financial information for Inventiva SA (IVA) listed on Euronext, specifically detailing its enterprise value to EBIT forward. It is presented within the TradingView platform, indicating market closure and no recent trades. The content primarily focuses on the", "url": "https://www.tradingview.com/symbols/EURONEXT-IVA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:22", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA Guggenheim Emerging Outlook: Biotech Summit 2026 Transcript", "summary": "This article provides a transcript from the Inventiva SA Guggenheim Emerging Outlook: Biotech Summit 2026, held on February 11, 2026. During the summit, Inventiva's CEO Andrew Obenshein discussed the company's activities, including an upcoming Phase 3 study readout, which was hig", "url": "https://www.gurufocus.com/stock/XPAR:IVA/transcripts/8608208", "source_name": "GuruFocus", "published_at": "2026-06-24T11:09:50", "published_display": "24 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVENTIVA SA (IVA.PA) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE15R3lfZ096S2NPU3RZc09oMk9MbzF4MTZXeFFBQXp3YTdUdDFfRXRNUkdaVVhXd19tRGt6eUh4aks0Und3RWVVVGR5YldfeS1waXhyNkJuajYzVURyRk5oeTN3UDVDM1E?oc=5", "source_name": "ChartMill", "published_at": "2026-06-19T17:00:00+00:00", "published_display": "19 Jun 2026 17:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA (IVA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Inventiva SA (IVA), highlighting a \"Strong Buy\" analyst rating based on 12 analysts, with a target price indicating a 243.00% upside. It includes key financial metrics like market capitalization and current stock price, along with a ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iva/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:12", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA (IVA) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Inventiva SA's (IVA) institutional confidence, detailing significant shareholders and their recent activity. Key institutional holders include Samsara BioCapital, Paradigm BioCapital Advisors, and Deep Track Capital, with notab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iva/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:12", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA (IVA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Inventiva SA (IVA), identifying major individual and institutional holders. It provides a breakdown of shareholders by type (e.g., Hedge Fund, Venture Capital) and tracks changes in institutional shareholding over recent quarters.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iva/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T18:09:39", "published_display": "17 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA (IVA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Inventiva SA (IVA) stock information, focusing on its dividend and stock split history. It states that Inventiva SA has not distributed any dividends over the past five years and has no recorded stock split data. The page also displays current", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iva/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:09:39", "published_display": "17 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Claret Capital Partners participates in \u20ac130m financing for Inventiva to support Phase 3 development", "summary": "Claret Capital Partners has participated in a \u20ac130 million financing round for Inventiva, a biopharmaceutical company developing an oral treatment for chronic liver disease, MASH. Claret is providing \u20ac43 million of growth funding to support Inventiva's lanifibranor, currently in ", "url": "https://ca.finance.yahoo.com/news/claret-capital-partners-participates-130m-085200433.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-16T08:40:34", "published_display": "16 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Claret Capital Partners participates in \u20ac130m financing for Inventiva", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOd2liT2JDS3Rfckx1UUJWTWlVS3BMcjNVdTRxZTkzYVFtdThuWTFpeWp6Mm4xVGw5R3dCbHlveUNoYVREVmNZamswd2lpSjFGYkdGOHdZd200QjJseXI3SEFYbUxPV0tjNTBKcWQ5VmlrdlBrb2Y5Zk4xMmNRd3g0T3Z0V2JzNUZJcW5ZMEdVUUJkRWFRNHNFOEdnSnpsdEptaWplUWpjTm85Mmw5U05DdThyTWxSRWFxY1lrcWJPMUFCOXZpT2xUTHlkQno0eU5haGl0SUZFYw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva (NASDAQ: IVA) refinances EIB debt with \u20ac75m bonds and new warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPVnZhMkpLbEhuRlRRekNGQUctQ1VjcVJQNmE0VG51NXJNcklGSFR0V1hhYmQxZzgxMFBuVzlnak1HVk9DajBDTEpDN25aOWVERVJrRUk3X3lUWWUwMjlSTjR4aDVWRW16SzV0dVB2VW1rV2tKY0FtYlg3ZVJodzFlX2cxa2dsS2s2Z05WaFVwWHk0ckRBNEFyUGRneDUtRmFldTY1dERLQ0xJaFRY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOSUlQWVR4WUZhdnMwWDJfZGVUVEpMMGZidVdPdXRkaUtmWFNIWEhvaXpjZGxWcnFUaXhkNnM1SU1aal9QVVFmTW1zcERzNDUwWDFDT21LOGhyby1FREdqQnU0Mlg3M01Uc2VkOTc2UFpLOU14ajRvWGZDTjY5YmFRdnFRdEJ1d3pvOHc?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva (NASDAQ: IVA) adds EIB warrant deal to June 30 2026 meeting agenda", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNdEtINzdnUjM3VTZMS3ltVG5LLWpsbnBtcWZKd1dNU2lGaVBZazI5eGFLTGJzVnhsakJncFJQVHBtN0s4YWNubUJwZDdVdU5iYWxvNnpzQ0hIc2U3NU9LMzNsZmNkSGEtaHRLOVBqS1l1REZ1T3NpRWgtMUlYQzUzS1dIcE9oekl4VkFSMm1yZkdkRmliaUhQak9TUDNqMjRkWnZsSTBMeWJqOVhE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T20:50:03+00:00", "published_display": "09 Jun 2026 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva S.A. (IVA) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow (NASDAQ:IVA) 2026-06-04", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNc3B6bTZ0SVJVdXpvMHZMZkhSVzc5THhrRUpOamtYSzFxWGFPWk9PNlNpV25KVEx2YjZuLWdfUzJGM0VLbzQxbFRCY0xUbXlIcVRveG43Z1VZZWVGVGo2WkZxNFRDVzZHNHhBOFhPV2tKN2xkTjRjbS1HQU5RdkFYektGb3djM05mT2U1djg2ZWxrVHVuUElmdVdTc2NjX0owdWs1Ty1FeHNZemJocEM3bDZ1enFpdXVTU0lCZDFIcWRIUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva (IVA) outlines ADS holder voting steps for June 30, 2026 General Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQeDV1MGZjZzRiaW82YW9Bc0V3Z0lxdXVCSzY5b05HQXdJZV9lNXpKSUFDRnA4QzJBNmlHdmpNOVVnajJqeVNRb2JxbVRIX0NuOFd1a2R6Rk5qSTVMZHZoMmZsRlBVcWx4WE5LOXlKM05pTV9UY0VqZUtOcFhKX2w5eWxra1Yzd0JuamE5cXFSZEh6VUJYY1FVM2tBdDlqdVBKVmFrYWhlbHZwUE1Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNODRqN3dNaEU1LW1qZmlOcGduUkxKUUd3NFVGc1BTRnZLZ2FGUEFhRVFrMkM4d04zNUthcDMyQXhiY1N1Vjd1ZklmT1U1aWlkUzdMOGMyUzZuS2FaeHh2elFBbkRoZjFFX0hvYzBXeXJ4TWlBalRqYkt1d2IxZWc4bEpxTi1MSlpnaEl5ektiZWV5Z0dVejZXTW1yNzM3bWFxLWRkVnF5dUhLSDFiU290MHpn?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNb0pQQ3hKQ0MwWmZnYzVBaUZRVjM2b2k3b0ZrTlAyc25lczU1aVFCdURtbzMyVVNUbmZXX1IwWmRTWjZYT2E2SHIwd09GcmFMcHFjRzVCYmY4NHBoVWxQY0VWTlBfemhPWl9jUXoxV2FOY0lWc0I0ZjQ1UTBKV3h1TlZpek10ZzJtb1NhbWNUdFhPRVYwU1dBdS0xTHRfUnlMOW52ZHRubkVNLTA?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Inventiva (ENXTPA:IVA) Valuation As Losses Deepen And MASH Trial Progresses", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdFNIYWlJNzZzdm9lNDdoN3ZEUjNKeGVpbjBiRG42dEVFNkVPaXROLWpFanhaelE2UDh2RzNyRlB4aWd0TmYtS0RYUG9CX0NHQTBERm15elFadzBaUGpXLTdNa3JCOXFwajFHTGhsS3VhVUFzZHZnV2U0dFd4MkJlbTZBeVNTbmpQMlV4MWp0YkJvN2lJZ1lKMl9Qb2tncTg3NkxXMmU4dXg?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva\u2019s Speculative Upside Through MASH Is Promising (NASDAQ:IVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOT29rU3hyNklUR2dTaUdzOEhqdGZ6UWY2anZGQXctNG9MXzh1U3ptRDhzb2FINGxZa0JYYTZMWnFhSHB3Y3dBWmtuYVFkRlUyWTFoS0xoNk5YbWFJSVgwUXRHb3c5dGppTXJEb0pFTXd6T0tFUTR6bEltSGdRQU5yNDI3Y3FRWE9uSExBNV9VX2RZT21jeUE2UnY0TDI?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Inventiva (ENXTPA:IVA) Story Is Shifting With Lanifibranor And Analyst Revisions", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOZS1xYkhJX0dxZlhWd3FBYkpqb3FwT2FYbm02QXgwSFh3R2tkRE9mOVZ5MmNpNEVrS3hDaEN6c0xZSlp1T1FJSDFDOXRoazNibWJvWjdQMjhKcmRaQzBCMjBFbHRNanJkTUtvaE4yN0k0MnNXQjU2Q1htZ3NJc0QxaTl4bWhZZm5DNGl3aktsdzc4N0puVVg4V0pNNmdaVVpQODhpVU5YSQ?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Inventiva (IVA) Stock Price, News & Analysis $IVA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTFBnNVdDUXh2R1c1WXUtY2ozZnJ6WWFNdkItQmY3bEl1ekI2U3BiZEVvVXlNcXRzTnRJdTJrbDVpWWRBaU1vWHJneEliREdBXy1EdzU3bnByS0k?oc=5", "source_name": "MarketBeat", "published_at": "2020-09-21T03:01:58+00:00", "published_display": "21 Sep 2020 03:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Inventiva (ENXTPA:IVA) Refreshes Its Board, Is The 62% Discount Too Wide?", "summary": "Inventiva (ENXTPA:IVA) has recently revamped its board with three new independent members, drawing investor attention. The company's stock is currently trading at a 62% discount to analyst targets, with a narrative fair value of \u20ac10.09 compared to its current price of \u20ac3.82, fuel", "url": "https://simplywall.st/stocks/fr/pharmaceuticals-biotech/epa-iva/inventiva-shares/news/inventiva-enxtpaiva-refreshes-its-board-is-the-62-discount-t/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T15:40:49", "published_display": "15 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring", "summary": "Inventiva S.A. (NASDAQ: IVA) has completed the restructuring of its European Investment Bank (EIB) warrants, issuing approximately 15.7 million new warrants and canceling original EIB warrants from January 2024. This move, according to CEO Andrew Obenshain, strengthens the compan", "url": "https://finance.yahoo.com/markets/stocks/articles/inventiva-iva-announces-issuance-eib-085308516.html", "source_name": "Market source", "published_at": "2026-07-15T03:53:00", "published_display": "15 Jul 2026 03:53", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva (ENXTPA:IVA) Puts Its MASH Narrative To The Test After A Recent Rebound", "summary": "Inventiva (ENXTPA:IVA) stock has experienced mixed performance, with recent gains offset by longer-term declines, as investors focus on its clinical pipeline in MASH and rare diseases. The company's MASH drug, lanifibranor, is in a Phase III trial, with top-line results expected ", "url": "https://finance.yahoo.com/healthcare/articles/inventiva-enxtpa-iva-puts-mash-130821487.html", "source_name": "Market source", "published_at": "2026-07-12T12:40:27", "published_display": "12 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Issues 15.7 Million New Warrants to the EIB and Completes Its Refinancing", "summary": "Inventiva has completed the final step of its financial restructuring by issuing approximately 15.7 million new warrants to the European Investment Bank (EIB) and cancelling unredeemed old warrants. This action simplifies the capital structure by eliminating anti-dilutive mechani", "url": "https://www.ideal-investisseur.fr/en/stock-news/inventiva-issues-15-7-million-new-warrants-to-the-eib-and-completes-its-refinancing/22487.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-10T10:28:56", "published_display": "10 Jul 2026 10:28", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Inventiva S.A. Current Report (Foreign Issuer) | IVA SEC Filing - Form 6-K", "summary": "Inventiva S.A. has completed its warrant restructuring with the European Investment Bank (EIB), issuing 15,677,573 new EIB warrants and cancelling all remaining legacy Tranche B warrants. This move simplifies the company's capital structure by removing specific contractual anti-d", "url": "https://www.stocktitan.net/sec-filings/IVA/6-k-inventiva-s-a-current-report-foreign-issuer-57e82f83c317.html", "source_name": "Stock Titan", "published_at": "2026-07-10T04:41:07", "published_display": "10 Jul 2026 04:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants", "summary": "Inventiva has completed the final step of its EIB warrant restructuring, issuing approximately 15.7 million new warrants to the European Investment Bank and canceling remaining legacy warrants. This initiative, part of a broader refinancing effort, aims to strengthen Inventiva's ", "url": "https://www.globenewswire.com/news-release/2026/07/09/3325223/0/en/inventiva-announces-completion-of-the-eib-warrant-restructuring-with-the-issuance-of-new-eib-warrants.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T20:08:56", "published_display": "09 Jul 2026 20:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Appoints Three Independent Directors Ahead of Key Lanifibranor Phase", "summary": "Inventiva has appointed three independent directors, Dr. Barbara Krebs-Pohl, Dr. Anne Prener, and Camilla Soenderby, to its board, effective June 30, 2026. These appointments aim to strengthen expertise in clinical development, commercialization, and financial strategy as the bio", "url": "https://www.ideal-investisseur.fr/en/stock-news/inventiva-appoints-three-independent-directors-ahead-of-key-lanifibranor-phase/22421.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-09T10:15:00", "published_display": "09 Jul 2026 10:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva S.A. - American Depository Shares Stock 12\u2011Month Price Target Raised to $15.69, Implies 257% Upside", "summary": "Inventiva S.A. (IVA) has seen its average 12-month price target raised from $15.08 to $15.69 by a consensus of 7 analysts, with individual forecasts ranging from $10 to $26 per share. This new target implies a substantial 257% potential upside based on the July 8 closing price. T", "url": "https://www.tradingview.com/news/tradingview:31235dc3185b4:0-inventiva-s-a-american-depository-shares-stock-12-month-price-target-raised-to-15-69-implies-257-upside/", "source_name": "TradingView", "published_at": "2026-07-09T04:19:41", "published_display": "09 Jul 2026 04:19", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva (NASDAQ: IVA) shareholders approve most 2026 meeting resolutions", "summary": "Inventiva S.A. shareholders approved almost all resolutions at their Combined Shareholders\u2019 General Meeting on June 30, 2026, with a quorum of over 71%. The only resolution rejected was the 31st, which would have authorized share capital increases for a company savings plan, alig", "url": "https://www.stocktitan.net/sec-filings/IVA/6-k-inventiva-s-a-current-report-foreign-issuer-31be093c8415.html", "source_name": "Stock Titan", "published_at": "2026-07-06T10:11:48", "published_display": "06 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6IVA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Inventiva SA ADR (6IVA) for 2027 based on analyst ratings. It states that 10 analysts offer 1-year price forecasts, but the specific maximum and minimum estimates are not provided. The content also includes a disclaimer that it", "url": "https://www.tradingview.com/symbols/MUN-6IVA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-04T04:39:43", "published_display": "04 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVA News | INVENTIVA SA - ADR (NASDAQ:IVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE96OEFrRWxIU29XSlphbzI1SVl4U1dRNDdoeHpZSDk5anNOalZObkZnRmFHNWlteldxeXBTS1pGczYta1I2aU45bzJVWnVPMzVISjNWdXFzaUdYUQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:02+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVENTIVA", "summary": "Inventiva, a clinical-stage biopharmaceutical company, announced the results of its Combined Shareholders' General Meeting held on June 30, 2026. Shareholders adopted all resolutions except for the 31st, which was related to share capital increases for a company savings plan and ", "url": "https://via.ritzau.dk/pressemeddelelse/15030111/inventiva?publisherId=90446&lang=en", "source_name": "Via Ritzau", "published_at": "2026-07-02T19:39:38", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Maintains Inventiva(IVA.US) With Buy Rating", "summary": "Truist Financial has reiterated its Buy rating on Inventiva (IVA.US) stock. The firm's decision to maintain this rating suggests a positive outlook on Inventiva's future performance.", "url": "https://www.moomoo.com/news/post/72400019/truist-financial-maintains-inventiva-ivaus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-07-02T15:39:39", "published_display": "02 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Calls June 30, 2026 Shareholder Meeting to Approve 2025 Accounts and New Capital Authorities", "summary": "Inventiva has scheduled a shareholder meeting for June 30, 2026, to approve its 2025 accounts, decide on profit allocation, executive compensation, and undertake board renewals and new appointments, signifying a comprehensive governance update. Shareholders will also vote on exte", "url": "https://www.tipranks.com/news/company-announcements/inventiva-calls-june-30-2026-shareholder-meeting-to-approve-2025-accounts-and-new-capital-authorities", "source_name": "TipRanks", "published_at": "2026-07-01T03:10:41", "published_display": "01 Jul 2026 03:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva S.A. (IVA) is One of the Best Stocks Under $10 Offering More Than 50% Upside", "summary": "Inventiva S.A. (NASDAQ: IVA) has a strong bullish consensus from analysts, with all 9 providing Buy ratings and a median 1-year price target of $15.75, implying over 325% upside. The company recently announced financial updates, including repaying \u20ac62 million of EIB loans, buying", "url": "https://finance.yahoo.com/markets/stocks/articles/inventiva-iva-one-best-stocks-163452236.html", "source_name": "Market source", "published_at": "2026-07-01T01:40:11", "published_display": "01 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNZFN2bDBwellQZG9YQmNEUk1TU0RfN3VSTGZ4MEV1amRGZ09Oa1hrY2VVRnZqSzdRV0ZXeTI3SURoQ0xzaHZvTEhHYW1ISHZkTlh5dHNfci1UNTZNNUlGZ29qbmdraldINFN6N1JzMnNlX3VqdXVUU2ZlYXhYbjRSVlk1bmMxeUNpQWpNRThNdw?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Inventiva SA \u2013 AQUISEU:IVAP", "summary": "This article provides financial information for Inventiva SA (IVAP) listed on the Aquis Stock Exchange, specifically focusing on its forward price-to-earnings ratio. The page details that the market is currently closed and no trades have occurred for IVAP. It presents a structure", "url": "https://www.tradingview.com/symbols/AQUISEU-IVAP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T12:40:24", "published_display": "27 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Inventiva SA \u2013 EURONEXT:IVA", "summary": "This article provides the \"Price to earnings forward\" value for Inventiva SA (EURONEXT:IVA). It states that the period value and change are presented, with the data made by humans. The content is primarily a data point display within the TradingView platform.", "url": "https://www.tradingview.com/symbols/EURONEXT-IVA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:40:53", "published_display": "27 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA ADR Actuals & Estimates (LSX:A2P796)", "summary": "The article provides an overview of Inventiva SA ADR's financial actuals and estimates for its stock (LSX:A2P796) on the Lang & Schwarz Exchange. It highlights the availability of reported financial data and analyst estimates across various financial statements, allowing users to", "url": "https://www.tradingview.com/symbols/LSX-A2P796/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:40:53", "published_display": "27 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA ADR Actuals & Estimates (LS:A2P796)", "summary": "This page provides financial actuals and estimates for Inventiva SA ADR (LS:A2P796), allowing users to explore reported financial data and analyst estimates. It covers the income statement, balance sheet, and cash flow, enabling comparison of actual results with average, high, an", "url": "https://www.tradingview.com/symbols/LS-A2P796/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:53", "published_display": "26 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Inventiva SA (IVA) stock, based on analyst opinions. It details current stock performance, historical highs and lows, and financial metrics such as market capitalization, earnings, and revenue. The article also includes freque", "url": "https://www.tradingview.com/symbols/EURONEXT-IVA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T11:40:53", "published_display": "26 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA Actuals & Estimates (EURONEXT:IVA)", "summary": "This article provides an overview of Inventiva SA's (EURONEXT:IVA) financial actuals and estimates. It covers historical stock performance, analyst forecasts, market capitalization, earnings reports, and other key financial metrics. The article also addresses frequently asked que", "url": "https://www.tradingview.com/symbols/EURONEXT-IVA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:40:53", "published_display": "26 Jun 2026 11:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Inventiva SA \u2013 EURONEXT:IVA", "summary": "This article presents the enterprise value to EBITDA forward data for Inventiva SA (EURONEXT:IVA) as reported on TradingView. It details the financial metric value and its period, along with any changes, but without providing specific figures. The content appears to be a financia", "url": "https://www.tradingview.com/symbols/EURONEXT-IVA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T07:39:19", "published_display": "26 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA ADR Actuals & Estimates (NASDAQ:IVA)", "summary": "This article provides access to the financial actuals and estimates for Inventiva S.A. - American Depository Shares (NASDAQ:IVA). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics,", "url": "https://www.tradingview.com/symbols/NASDAQ-IVA/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T06:39:19", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Inventiva SA \u2013 EURONEXT:IVA", "summary": "The article provides financial information for Inventiva SA (IVA) listed on Euronext, specifically detailing its enterprise value to EBIT forward. It is presented within the TradingView platform, indicating market closure and no recent trades. The content primarily focuses on the", "url": "https://www.tradingview.com/symbols/EURONEXT-IVA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:22", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA Guggenheim Emerging Outlook: Biotech Summit 2026 Transcript", "summary": "This article provides a transcript from the Inventiva SA Guggenheim Emerging Outlook: Biotech Summit 2026, held on February 11, 2026. During the summit, Inventiva's CEO Andrew Obenshein discussed the company's activities, including an upcoming Phase 3 study readout, which was hig", "url": "https://www.gurufocus.com/stock/XPAR:IVA/transcripts/8608208", "source_name": "GuruFocus", "published_at": "2026-06-24T11:09:50", "published_display": "24 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVENTIVA SA (IVA.PA) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE15R3lfZ096S2NPU3RZc09oMk9MbzF4MTZXeFFBQXp3YTdUdDFfRXRNUkdaVVhXd19tRGt6eUh4aks0Und3RWVVVGR5YldfeS1waXhyNkJuajYzVURyRk5oeTN3UDVDM1E?oc=5", "source_name": "ChartMill", "published_at": "2026-06-19T17:00:00+00:00", "published_display": "19 Jun 2026 17:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA (IVA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Inventiva SA (IVA), highlighting a \"Strong Buy\" analyst rating based on 12 analysts, with a target price indicating a 243.00% upside. It includes key financial metrics like market capitalization and current stock price, along with a ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iva/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:12", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA (IVA) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Inventiva SA's (IVA) institutional confidence, detailing significant shareholders and their recent activity. Key institutional holders include Samsara BioCapital, Paradigm BioCapital Advisors, and Deep Track Capital, with notab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iva/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:12", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA (IVA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Inventiva SA (IVA), identifying major individual and institutional holders. It provides a breakdown of shareholders by type (e.g., Hedge Fund, Venture Capital) and tracks changes in institutional shareholding over recent quarters.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iva/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T18:09:39", "published_display": "17 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva SA (IVA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Inventiva SA (IVA) stock information, focusing on its dividend and stock split history. It states that Inventiva SA has not distributed any dividends over the past five years and has no recorded stock split data. The page also displays current", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iva/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:09:39", "published_display": "17 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Claret Capital Partners participates in \u20ac130m financing for Inventiva to support Phase 3 development", "summary": "Claret Capital Partners has participated in a \u20ac130 million financing round for Inventiva, a biopharmaceutical company developing an oral treatment for chronic liver disease, MASH. Claret is providing \u20ac43 million of growth funding to support Inventiva's lanifibranor, currently in ", "url": "https://ca.finance.yahoo.com/news/claret-capital-partners-participates-130m-085200433.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-16T08:40:34", "published_display": "16 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Claret Capital Partners participates in \u20ac130m financing for Inventiva", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOd2liT2JDS3Rfckx1UUJWTWlVS3BMcjNVdTRxZTkzYVFtdThuWTFpeWp6Mm4xVGw5R3dCbHlveUNoYVREVmNZamswd2lpSjFGYkdGOHdZd200QjJseXI3SEFYbUxPV0tjNTBKcWQ5VmlrdlBrb2Y5Zk4xMmNRd3g0T3Z0V2JzNUZJcW5ZMEdVUUJkRWFRNHNFOEdnSnpsdEptaWplUWpjTm85Mmw5U05DdThyTWxSRWFxY1lrcWJPMUFCOXZpT2xUTHlkQno0eU5haGl0SUZFYw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva (NASDAQ: IVA) refinances EIB debt with \u20ac75m bonds and new warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPVnZhMkpLbEhuRlRRekNGQUctQ1VjcVJQNmE0VG51NXJNcklGSFR0V1hhYmQxZzgxMFBuVzlnak1HVk9DajBDTEpDN25aOWVERVJrRUk3X3lUWWUwMjlSTjR4aDVWRW16SzV0dVB2VW1rV2tKY0FtYlg3ZVJodzFlX2cxa2dsS2s2Z05WaFVwWHk0ckRBNEFyUGRneDUtRmFldTY1dERLQ0xJaFRY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOSUlQWVR4WUZhdnMwWDJfZGVUVEpMMGZidVdPdXRkaUtmWFNIWEhvaXpjZGxWcnFUaXhkNnM1SU1aal9QVVFmTW1zcERzNDUwWDFDT21LOGhyby1FREdqQnU0Mlg3M01Uc2VkOTc2UFpLOU14ajRvWGZDTjY5YmFRdnFRdEJ1d3pvOHc?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva (NASDAQ: IVA) adds EIB warrant deal to June 30 2026 meeting agenda", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNdEtINzdnUjM3VTZMS3ltVG5LLWpsbnBtcWZKd1dNU2lGaVBZazI5eGFLTGJzVnhsakJncFJQVHBtN0s4YWNubUJwZDdVdU5iYWxvNnpzQ0hIc2U3NU9LMzNsZmNkSGEtaHRLOVBqS1l1REZ1T3NpRWgtMUlYQzUzS1dIcE9oekl4VkFSMm1yZkdkRmliaUhQak9TUDNqMjRkWnZsSTBMeWJqOVhE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T20:50:03+00:00", "published_display": "09 Jun 2026 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva S.A. (IVA) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow (NASDAQ:IVA) 2026-06-04", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNc3B6bTZ0SVJVdXpvMHZMZkhSVzc5THhrRUpOamtYSzFxWGFPWk9PNlNpV25KVEx2YjZuLWdfUzJGM0VLbzQxbFRCY0xUbXlIcVRveG43Z1VZZWVGVGo2WkZxNFRDVzZHNHhBOFhPV2tKN2xkTjRjbS1HQU5RdkFYektGb3djM05mT2U1djg2ZWxrVHVuUElmdVdTc2NjX0owdWs1Ty1FeHNZemJocEM3bDZ1enFpdXVTU0lCZDFIcWRIUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva (IVA) outlines ADS holder voting steps for June 30, 2026 General Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQeDV1MGZjZzRiaW82YW9Bc0V3Z0lxdXVCSzY5b05HQXdJZV9lNXpKSUFDRnA4QzJBNmlHdmpNOVVnajJqeVNRb2JxbVRIX0NuOFd1a2R6Rk5qSTVMZHZoMmZsRlBVcWx4WE5LOXlKM05pTV9UY0VqZUtOcFhKX2w5eWxra1Yzd0JuamE5cXFSZEh6VUJYY1FVM2tBdDlqdVBKVmFrYWhlbHZwUE1Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNODRqN3dNaEU1LW1qZmlOcGduUkxKUUd3NFVGc1BTRnZLZ2FGUEFhRVFrMkM4d04zNUthcDMyQXhiY1N1Vjd1ZklmT1U1aWlkUzdMOGMyUzZuS2FaeHh2elFBbkRoZjFFX0hvYzBXeXJ4TWlBalRqYkt1d2IxZWc4bEpxTi1MSlpnaEl5ektiZWV5Z0dVejZXTW1yNzM3bWFxLWRkVnF5dUhLSDFiU290MHpn?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNb0pQQ3hKQ0MwWmZnYzVBaUZRVjM2b2k3b0ZrTlAyc25lczU1aVFCdURtbzMyVVNUbmZXX1IwWmRTWjZYT2E2SHIwd09GcmFMcHFjRzVCYmY4NHBoVWxQY0VWTlBfemhPWl9jUXoxV2FOY0lWc0I0ZjQ1UTBKV3h1TlZpek10ZzJtb1NhbWNUdFhPRVYwU1dBdS0xTHRfUnlMOW52ZHRubkVNLTA?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Inventiva (ENXTPA:IVA) Valuation As Losses Deepen And MASH Trial Progresses", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdFNIYWlJNzZzdm9lNDdoN3ZEUjNKeGVpbjBiRG42dEVFNkVPaXROLWpFanhaelE2UDh2RzNyRlB4aWd0TmYtS0RYUG9CX0NHQTBERm15elFadzBaUGpXLTdNa3JCOXFwajFHTGhsS3VhVUFzZHZnV2U0dFd4MkJlbTZBeVNTbmpQMlV4MWp0YkJvN2lJZ1lKMl9Qb2tncTg3NkxXMmU4dXg?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva\u2019s Speculative Upside Through MASH Is Promising (NASDAQ:IVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOT29rU3hyNklUR2dTaUdzOEhqdGZ6UWY2anZGQXctNG9MXzh1U3ptRDhzb2FINGxZa0JYYTZMWnFhSHB3Y3dBWmtuYVFkRlUyWTFoS0xoNk5YbWFJSVgwUXRHb3c5dGppTXJEb0pFTXd6T0tFUTR6bEltSGdRQU5yNDI3Y3FRWE9uSExBNV9VX2RZT21jeUE2UnY0TDI?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Inventiva (ENXTPA:IVA) Story Is Shifting With Lanifibranor And Analyst Revisions", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOZS1xYkhJX0dxZlhWd3FBYkpqb3FwT2FYbm02QXgwSFh3R2tkRE9mOVZ5MmNpNEVrS3hDaEN6c0xZSlp1T1FJSDFDOXRoazNibWJvWjdQMjhKcmRaQzBCMjBFbHRNanJkTUtvaE4yN0k0MnNXQjU2Q1htZ3NJc0QxaTl4bWhZZm5DNGl3aktsdzc4N0puVVg4V0pNNmdaVVpQODhpVU5YSQ?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventiva (IVA) Stock Price, News & Analysis $IVA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTFBnNVdDUXh2R1c1WXUtY2ozZnJ6WWFNdkItQmY3bEl1ekI2U3BiZEVvVXlNcXRzTnRJdTJrbDVpWWRBaU1vWHJneEliREdBXy1EdzU3bnByS0k?oc=5", "source_name": "MarketBeat", "published_at": "2020-09-21T03:01:58+00:00", "published_display": "21 Sep 2020 03:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 53, "sentiment_summary": {"positive": 12, "negative": 4, "neutral": 37, "score": 54, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 12.25, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 4.3, "latest_week": "2026-07-10", "one_week_move": 10.0, "four_week_move": 11.7, "twelve_week_move": -24.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.121833, "market_dynamics_buy_signal": false, "relative_strength": -26.695569, "fair_value_gap": 12.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.8167, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+10.0% over one week, +11.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "TradingView", "count": 12}, {"label": "Stock Titan", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "Id\u00e9al Investisseur", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "ChartMill", "count": 2}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 7}, {"label": "Balance sheet", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+10.0% over one week, +11.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Inventiva (ENXTPA:IVA) Refreshes Its Board, Is The 62% Discount Too Wide?"}], "updated_at": "2026-07-16T19:33:07.679450+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}